Julie Hambleton
About Julie Hambleton
Julie Hambleton, M.D., age 67, is an independent Class II director of Erasca, Inc., serving since March 2021; her current term runs to the 2026 annual meeting. She is a hematologist-oncologist and biopharma executive who previously served as SVP/Chief Medical Officer/Head of Development at IDEAYA, VP Head US Medical at Bristol-Myers Squibb, EVP/CMO at Five Prime Therapeutics, VP Clinical Development at Clovis Oncology, and held senior BioOncology roles at Genentech; she trained in heme/onc at UCSF (faculty 1993–2003), holds a B.S. in Nursing (Duke) and M.D. (Case Western), and was board-certified in hematology and internal medicine .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| IDEAYA Biosciences | SVP, Chief Medical Officer, Head of Development | Jun 2018 – Apr 2020 (retired) | Led development in oncology medicines |
| Arch Therapeutics (private) | Interim President & CEO | Aug 2020 – Mar 2021 | Interim leadership during transition |
| Bristol-Myers Squibb | Vice President, Head US Medical | May 2016 – Sep 2017 | US medical leadership |
| Five Prime Therapeutics | EVP & Chief Medical Officer; earlier SVP & CMO | Aug 2015 – Feb 2016; Dec 2012 – Aug 2015 | Clinical leadership |
| Clovis Oncology | Vice President, Clinical Development | Apr 2010 – Nov 2012 | Clinical development |
| Genentech | Roles of increasing responsibility, BioOncology | 2003 – 2010 | Oncology development |
| UCSF | Hematology-Oncology training; Faculty | Training; Faculty 1993 – 2003 | Academic/clinical practice |
External Roles
| Company | Role | Public/Private | Start |
|---|---|---|---|
| IGM Biosciences, Inc. | Director | Public | Aug 2018 |
| SpringWorks Therapeutics, Inc. | Director | Public | May 2020 |
Board Governance
- Independence: The Board has determined Dr. Hambleton is independent under Nasdaq listing rules; she is listed as an independent Class II director (term expiring 2026) .
- Committee assignments (2024/2025): Audit Committee (member); Compensation Committee (member). Audit Committee chaired by Alexander W. Casdin; Compensation Committee chaired by James A. Bristol .
- Meeting cadence: Board met six times in 2024; each director attended at least 75% of Board and relevant committee meetings. Audit met 4x; Compensation met 5x; Nominating & Corporate Governance met 2x .
- Responsibilities touchpoints: Audit oversees financial reporting, related-party review, and cybersecurity risk; Compensation oversees executive and director pay and uses independent consultant Alpine Rewards (no conflicts) .
- Governance policies: Prohibits pledging/hedging, margin, short sales, and derivatives on company stock; Code of Ethics and Insider Trading Policy apply to directors .
- Board structure context: Classified (staggered) board; directors removable only for cause with supermajority—a potential entrenchment factor at the board level (not director-specific) .
Fixed Compensation
| Component (Non-Employee Director) | Amount (USD) | Notes |
|---|---|---|
| Annual Board retainer (2024) | $40,000 | Standard cash retainer |
| Audit Committee member retainer (2024) | $7,500 | Member retainer |
| Compensation Committee member retainer (2024) | $5,000 | Member retainer |
| Total fees earned/paid in cash (2024) | $52,500 | As reported for Dr. Hambleton |
- Program updates effective 2025: Compensation Committee chair/member retainers increased to $12,000/$6,000; Nominating & Corporate Governance chair/member to $10,000/$5,000 .
Performance Compensation
| Equity/Policy Item | Detail |
|---|---|
| Option awards (grant-date fair value, 2024) | $85,866 for Dr. Hambleton |
| Options outstanding (12/31/2024) | 326,666 options |
| Annual director equity (2024 program) | Options to purchase 60,000 shares; vest at next AGM or 1-year anniversary |
| Initial director equity (pre-2025) | Options to purchase 120,000 shares; vest over three years |
| Program update (2025+) | Annual option grant increased to 120,000; initial grant increased to 240,000 |
| Retainer-in-options election | Directors may elect to receive cash retainers as options; footnotes list incremental values for certain directors (Dr. Hambleton is not listed among those electing in 2024) |
| Clawback | Company adopted a compensation recovery policy for certain erroneously paid incentive compensation to Section 16 officers on/after Oct 2, 2023, per SEC/Nasdaq rules |
Other Directorships & Interlocks
- Current public boards: IGM Biosciences (since Aug 2018); SpringWorks Therapeutics (since May 2020) .
- Compensation Committee interlocks: None—no executive officer interlocks and no committee member has served as an Erasca officer .
Expertise & Qualifications
- Medical and development leadership in oncology across Genentech, Clovis, Five Prime, BMS, and IDEAYA, with prior academic heme/onc practice at UCSF—strong fit for Erasca’s oncology focus .
- Education: B.S. Nursing (Duke), M.D. (Case Western), board-certified in hematology and internal medicine .
Equity Ownership
| Metric | Value |
|---|---|
| Beneficial ownership (shares) | 272,666 shares (as of April 15, 2025) |
| Ownership % of outstanding | Less than 1% of 283,265,716 shares outstanding |
| Options outstanding (12/31/2024) | 326,666 options |
| Methodology note | Beneficial ownership includes securities exercisable within 60 days per SEC rules |
| Hedging/pledging | Prohibited for directors under company policy |
Governance Assessment
- Strengths: Independent director with deep oncology development expertise; active on Audit and Compensation Committees; board-level policies prohibit pledging/hedging; use of independent comp consultant (no conflicts); attendance at or above minimum threshold (≥75% in 2024) .
- Alignment: Director pay combines cash retainers with meaningful option grants; program allows optional retainer-in-options and increased annual grants from 2025, potentially enhancing equity alignment. Dr. Hambleton received $52,500 in cash fees and $85,866 in option value in 2024; she is not listed among those who elected retainer-in-options in 2024 .
- Conflicts/related-party exposure: Audit Committee reviews related-party transactions; proxy discloses certain relationships (e.g., Erasca Foundation, legacy shareholder agreements) but none attributed to Dr. Hambleton; Compensation Committee interlocks explicitly “none” .
- Risk flags: None specific to Dr. Hambleton identified (no attendance shortfall, no related-party ties, no pledging). Board-level entrenchment features exist (classified board, removal for cause with supermajority) but are structural rather than director-specific. RED FLAG (board-level): staggered board with for-cause removal only may reduce accountability in contested scenarios .